uniQure (QURE) Expected to Announce Earnings on Wednesday

uniQure (NASDAQ:QURE) is expected to be announcing its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.60) per share and revenue of $18.45 million for the quarter.

uniQure Stock Performance

Shares of uniQure stock opened at $11.48 on Tuesday. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The firm has a market capitalization of $559.57 million, a P/E ratio of -2.31 and a beta of 0.39. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The business has a fifty day simple moving average of $15.50 and a two-hundred day simple moving average of $9.66.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on QURE. StockNews.com raised shares of uniQure to a “sell” rating in a report on Wednesday, February 5th. The Goldman Sachs Group increased their price objective on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 12th. HC Wainwright boosted their target price on uniQure from $25.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Stifel Nicolaus raised their price target on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a report on Monday, December 16th. Finally, Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.00.

Insider Buying and Selling at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.74% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.